top of page

Biopharma Daily Stock Updates - 08/12/21

$XBI $126.79 +0.9%


Pipeline Updates

$FUSN +1.2% Fusion Pharmaceuticals and TRIUMF Announce Expanded R&D Collaboration for Actinium Supply Production. source

$JAZZ +0.4% Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults. source

$VYNE -31.1% VYNE Therapeutics Announces Licensing of BET Inhibitor Platform for Immuno-Inflammatory Conditions with In4Derm Limited. source

$ALLO -0.4% Allogene Therapeutics Receives FDA Orphan Drug Designation (ODD) for ALLO-715 for the Treatment of Multiple Myeloma (MM). source

$CHRS +2.0% Junshi Biosciences and Coherus Announce U.S. FDA Breakthrough Therapy Designation Granted for Toripalimab for 1st Line Treatment of Nasopharyngeal Carcinoma. source

$LQDA +9.3% U.S. Patent Trial and Trademark Appeal Board Decides to Institute Inter Partes Review of United Therapeutics’ Tyvaso® Patent. source

$PHAS -1.5% PhaseBio Pharmaceuticals Achieves Enrollment Milestones Supporting Interim Analysis of REVERSE-IT Global Phase 3 Trial, Enabling Preparation of a BLA submission for Bentracimab for Reversal of Antiplatelet Effects of Ticagrelor. source

$APRE -1.5% Aprea Therapeutics Announces Clinical Hold on Lymphoid Malignancy Program. source

$ANGN -18.2% Angion Provides Corporate Update and Reports Second Quarter 2021 Financial Results. source

$NOVN +15.4% Novan Reports Second Quarter 2021 Financial Results and Provides Corporate Update. source

$LRMR +17.85 Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results. source

$SESN +21.5% Sesen Bio Strengthens Executive Leadership Team as the Company Approaches the Potential Approval and Commercial Launch of Vicineum™. source

Financial Updates

$CRMD +0.7% The Gross Law Firm Announces Class Actions on Behalf of Shareholders of OCGN, CRMD and AHCO. source

$CALT -2.9% Calliditas Therapeutics intends to carry out a directed share issue. source

$FULC +11.1% Fulcrum Therapeutics Announces Pricing of $125 Million Public Offering of Common Stock. source


Posted by FS



bottom of page